Skip to content
Open access

Venous Thromboembolism Risk Following Total Joint Arthroplasty in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors: A Propensity Score-Matched Cohort Study

Sep 2026 · Journal of Clinical Medicine · Vol 15, pp. 7098 · 0 citations · 21 references
Medicine

TL;DR

Among RA patients undergoing primary TJA, JAK inhibitor use was not associated with a statistically significant increase in postoperative VTE compared with TNF inhibitor use, although VTE events occurred numerically more often in the JAK inhibitor cohort.

Abstract

Background: Janus kinase (JAK) inhibitors have been linked to higher venous thromboembolism (VTE) rates than tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) populations, yet it is uncertain whether this risk extends postoperatively after total joint arthroplasty (TJA). Methods: A retrospective propensity score-matched cohort study was performed using a large federated network of de-identified electronic health records. Adults with RA undergoing primary total knee or hip arthroplasty were identified, and patients were categorized based on the use of a JAK inhibitor or a TNF inhibitor within 3 months of surgery. Propensity score matching was conducted in a 1:1 ratio based on demographics, comorbidities, and medications. The primary outcome was VTE, defined as deep vein thrombosis or pulmonary embolism occurring from postoperative day 1 through 365 days; patients with VTE prior to this window were excluded. Results: Before matching, 305 JAK inhibitor users and 1299 TNF inhibitor users met inclusion criteria; after propensity score matching, 304 patients remained in each cohort, and exclusion of patients with prior VTE yielded 284 JAK inhibitor users and 288 TNF inhibitor users for analysis. VTE occurred in 17 JAK inhibitor users (6.0%) and 11 TNF inhibitor users (3.8%), corresponding to a risk ratio of 1.57 (95% confidence interval [CI], 0.75–3.29; p = 0.230). Kaplan–Meier analysis demonstrated a hazard ratio of 1.56 (95% CI, 0.73–3.33), with no statistically significant difference between groups (log-rank p = 0.248). Conclusions: Among RA patients undergoing primary TJA, JAK inhibitor use was not associated with a statistically significant increase in postoperative VTE compared with TNF inhibitor use, although VTE events occurred numerically more often in the JAK inhibitor cohort. These findings do not exclude a clinically relevant increase in postoperative thrombotic risk with JAK inhibitors, and larger studies are required to clarify the magnitude of risk and to inform thromboprophylaxis strategies.

Read PDF

Similar papers

Open access Oct 2026

Estrogen hormonal therapy is not associated with increased risk of venous thrombosis in total hip arthroplasty or hemiarthroplasty for femoral neck fractures

Abstract Objectives: To evaluate the impact of estrogen hormone therapy on venous thrombotic events for femoral neck fractures treated with either total hip arthroplasty (THA) or hemiarthroplasty (HA). Methods: Design: Retrospective cohort analysis. Setting: TriNetX Health Research Network. Patient Selection Criteria:...

Andrew Ni, Lana Abdelrahim, Casey D. McDonald et al. · 0 citations
Mar 2026

GLP-1 Receptor Agonist Use before Total Knee Arthroplasty is Associated with Lower Postoperative MI, DVT, and VTE Rates

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight management, but their association with postoperative thrombotic events after total knee arthroplasty (TKA) remains unclear. We performed a retrospective cohort study using de-identified data from t...

Bryan Yavari, Aria Soltankhah, Nafis B. Eghrari et al. · 0 citations
Nov 2026

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

BACKGROUND Studies comparing aspirin with anticoagulants for venous thromboembolism (VTE) prophylaxis after total hip or knee arthroplasty have had conflicting results. METHODS In a comparative-effectiveness noninferiority trial, we randomly assigned patients undergoing elective hip or knee arthroplasty to receive as...

V. D. Pellegrini, Carol A. Lambourne, L. Magder et al. · 0 citations
Open access Sep 2026

Venous and arterial thromboembolic events associated with osimertinib in patients with lung cancer: a study by the thrombosis and cancer group of the spanish society of medical oncology (SEOM).

PURPOSE To determine the real-world clinical practice incidence and predictive factors of venous and arterial thromboembolic events (VTE/ATE) in lung cancer patients treated with osimertinib. METHODS/PATIENTS A multicenter retrospective study including 546 lung cancer patients who initiated treatment with osimertinib...

Manuel Sánchez Cánovas, Javier López Robles, C. Fernandez-Reino et al. · 0 citations
Sep 2026

The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty.

BACKGROUND Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly selective cyclooxygenase-2 (COX-2) inhibitors, are foundational to multimodal pain management following primary total-hip arthroplasty (THA) but concerns regarding bleeding often limit their use in patients receiving chronic anticoagulation. While d...

Sri Tummala, Angel A. Valencia, Antonia F. Chen et al. · 0 citations
Review Open access Oct 2026

Aspirin-Based Thromboprophylaxis Versus Anticoagulant Regimens After Total Hip or Knee Arthroplasty: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

The main pooled analyses associated aspirin-based thromboprophylaxis with higher risks of symptomatic thromboembolic events, however, the symptomatic DVT and symptomatic VTE associations were no longer statistically significant after exclusion of CRISTAL or restriction to trials at low risk of bias.

Hasan Al-Chalabi, Omar Amro, Amy Gordon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.